FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101352771> ?p ?o ?g. }

• W2101352771 endingPage "74" @default.
• W2101352771 startingPage "267" @default.
• W2101352771 abstract "Angiogenesis plays a pivotal role in tumor growth and represents a key target for chemopreventive intervention. On the basis of the structural features and lack of target organ specificity of the synthetic dithiolethione oltipraz, inhibition of angiogenesis was assessed as a potential mechanism for its broad-based chemopreventive activity. The effects of oltipraz on the development and maturation of a vascular network was determined in vitro using two-dimensional capillary tube formation assays with human umbilical vein endothelial cells plated on Matrigel and ex vivo using primary rat aortic ring explant cultures in three-dimensional collagen gels, respectively. The antiangiogenic and antitumor efficacy of oltipraz administration in vivo in nude mice was evaluated by determining its effects on neovascularization in s.c. Matrigel implants seeded with vascular endothelial growth factor and basic fibroblast growth factor-stimulated porcine aortic endothelial cells and on tumor growth and angiogenesis in SVR murine angiosarcoma xenografts implanted s.c. A dose-dependent reduction (0.4-100 microM) in microvessel formation was observed in both human and rodent bioassays after oltipraz exposure, with inhibition approaching 100% in the rat aortic ring assay at the highest concentration (P < 0.01). Similarly, oltipraz (40 microM) inhibited complete capillary tube formation by human umbilical vein endothelial cells by 62% (P < 0.05) relative to control cultures. p.o. administration of oltipraz (250 mg/kg/day for 6 days) to nude mice implanted with porcine aortic endothelial cell-Matrigel plugs resulted in a 42% reduction in neovascularization (P < 0.05) relative to vehicle-treated control mice. Administration of the same dose of oltipraz to athymic mice bearing established s.c. SVR angiosarcoma xenografts for 10 days resulted in a significant inhibition of tumor growth as early as day 4 of dosing (P < 0.005), with a maximum inhibition of tumor growth (81%, P < 0.001) relative vehicle-treated mice by day 10. The observed efficacy of oltipraz in this model is comparable with that of SU 5416 and TNP-470, known antiangiogenic agents currently under clinical development. Plasma levels of oltipraz at the termination of in vivo efficacy studies were 66.4 +/- 7 microM as determined by reversed phase high-performance liquid chromatography, a concentration range associated with significant antiangiogenic activity of oltipraz in vitro and ex vivo. These data suggest that the chemopreventive agent oltipraz may be effective in the treatment of advanced stage cancers and metastases, in part, because of its antiangiogenic activity in vivo." @default.
• W2101352771 created "2016-06-24" @default.
• W2101352771 creator A5016241152 @default.
• W2101352771 creator A5022569332 @default.
• W2101352771 creator A5029840953 @default.
• W2101352771 creator A5036665836 @default.
• W2101352771 creator A5086400213 @default.
• W2101352771 date "2002-01-01" @default.
• W2101352771 modified "2023-09-23" @default.
• W2101352771 title "The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth." @default.
• W2101352771 cites W151723881 @default.
• W2101352771 cites W1556877038 @default.
• W2101352771 cites W1558159075 @default.
• W2101352771 cites W1566059459 @default.
• W2101352771 cites W1619524329 @default.
• W2101352771 cites W1863333439 @default.
• W2101352771 cites W1931474544 @default.
• W2101352771 cites W1948311503 @default.
• W2101352771 cites W1969855058 @default.
• W2101352771 cites W1989617588 @default.
• W2101352771 cites W1998804929 @default.
• W2101352771 cites W2002502104 @default.
• W2101352771 cites W2008438789 @default.
• W2101352771 cites W2010435021 @default.
• W2101352771 cites W2045061052 @default.
• W2101352771 cites W2050067824 @default.
• W2101352771 cites W2061757494 @default.
• W2101352771 cites W2066711736 @default.
• W2101352771 cites W2112942470 @default.
• W2101352771 cites W2117013761 @default.
• W2101352771 cites W2117413404 @default.
• W2101352771 cites W2127921903 @default.
• W2101352771 cites W2131226298 @default.
• W2101352771 cites W2146651717 @default.
• W2101352771 cites W2146787008 @default.
• W2101352771 cites W2166825418 @default.
• W2101352771 cites W2170723552 @default.
• W2101352771 cites W2171887423 @default.
• W2101352771 cites W2212388853 @default.
• W2101352771 cites W2406728010 @default.
• W2101352771 cites W2407942580 @default.
• W2101352771 cites W2410953231 @default.
• W2101352771 cites W2413407405 @default.
• W2101352771 cites W3102812175 @default.
• W2101352771 cites W46759496 @default.
• W2101352771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11801568" @default.
• W2101352771 hasPublicationYear "2002" @default.
• W2101352771 type Work @default.
• W2101352771 sameAs 2101352771 @default.
• W2101352771 citedByCount "7" @default.
• W2101352771 countsByYear W21013527712014 @default.
• W2101352771 countsByYear W21013527712015 @default.
• W2101352771 crossrefType "journal-article" @default.
• W2101352771 hasAuthorship W2101352771A5016241152 @default.
• W2101352771 hasAuthorship W2101352771A5022569332 @default.
• W2101352771 hasAuthorship W2101352771A5029840953 @default.
• W2101352771 hasAuthorship W2101352771A5036665836 @default.
• W2101352771 hasAuthorship W2101352771A5086400213 @default.
• W2101352771 hasConcept C123012128 @default.
• W2101352771 hasConcept C150903083 @default.
• W2101352771 hasConcept C167734588 @default.
• W2101352771 hasConcept C185592680 @default.
• W2101352771 hasConcept C202751555 @default.
• W2101352771 hasConcept C207001950 @default.
• W2101352771 hasConcept C26291073 @default.
• W2101352771 hasConcept C2776056115 @default.
• W2101352771 hasConcept C2777025900 @default.
• W2101352771 hasConcept C2777411675 @default.
• W2101352771 hasConcept C2777834122 @default.
• W2101352771 hasConcept C2778271429 @default.
• W2101352771 hasConcept C2778608917 @default.
• W2101352771 hasConcept C2780394083 @default.
• W2101352771 hasConcept C502942594 @default.
• W2101352771 hasConcept C55493867 @default.
• W2101352771 hasConcept C71924100 @default.
• W2101352771 hasConcept C86803240 @default.
• W2101352771 hasConcept C98274493 @default.
• W2101352771 hasConceptScore W2101352771C123012128 @default.
• W2101352771 hasConceptScore W2101352771C150903083 @default.
• W2101352771 hasConceptScore W2101352771C167734588 @default.
• W2101352771 hasConceptScore W2101352771C185592680 @default.
• W2101352771 hasConceptScore W2101352771C202751555 @default.
• W2101352771 hasConceptScore W2101352771C207001950 @default.
• W2101352771 hasConceptScore W2101352771C26291073 @default.
• W2101352771 hasConceptScore W2101352771C2776056115 @default.
• W2101352771 hasConceptScore W2101352771C2777025900 @default.
• W2101352771 hasConceptScore W2101352771C2777411675 @default.
• W2101352771 hasConceptScore W2101352771C2777834122 @default.
• W2101352771 hasConceptScore W2101352771C2778271429 @default.
• W2101352771 hasConceptScore W2101352771C2778608917 @default.
• W2101352771 hasConceptScore W2101352771C2780394083 @default.
• W2101352771 hasConceptScore W2101352771C502942594 @default.
• W2101352771 hasConceptScore W2101352771C55493867 @default.
• W2101352771 hasConceptScore W2101352771C71924100 @default.
• W2101352771 hasConceptScore W2101352771C86803240 @default.
• W2101352771 hasConceptScore W2101352771C98274493 @default.
• W2101352771 hasIssue "1" @default.
• W2101352771 hasLocation W21013527711 @default.

• next